Events, By Category and Date:
» Go to news mainReviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected
Posted by nte on
July 2, 2018
in
In Print
Herder, M. (2018). Reviving the FDA's authority to publicly explain why new drug applications are approved or rejected. JAMA Intern Med. Published online 2 July 2018. doi:10.1001/jamainternmed.2018.3137
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize